课题基金 / 基金详情

项目摘要

项目成果

XIANGPENG KONG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Seeinstructions): Dr. Xiangpeng Kong's group at NYU School of Medicine will serve as the Structural Biology Core (SBC) for a Program Project entitled "Neutralizing antibodies targeting the CD4 binding region of HIV-1 ENV" in response to NIAID program announcement PAR-06-285, HIVVaccine Research and Design (HIVRAD). The team of this P01 includes, in addition to Dr. Kong's group, Drs. Shan Lu (PI, University of Massachusetts Medical School); Paul Clapham (University of Massachusetts Medical School); and Shiu-Lok Hu (University of Washington). Our SBC team is highly experienced in protein crystallography, cryo-electron microscopy and other biophysical techniques, and we will provide services for the P01 team in 3 areas: (i) using protein crystallographic methods to characterize a recombinant protein that mimics the CD4 binding site of HIV-1 gp120, and structural characterization of monoclonal antibodies generated by the P01 team; (ii)using surface plasma resonance (SPR) method to characterize the interactions between HIV-1 gp120 and its mutants with its receptor CD4 as well as antibodies against the HIV-1 surface protein; (iii)using computation method to characterize the structural dynamics of gp120 and its mutants. The structural information generated from our SBC will help the POTs aim in designing a vaccine against HIV-1. RELEVANCE (Seeinstructions):
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunogenicity of the newly identified V3 crown vulnerable site
Immunogenicity of the newly identified V3 crown vulnerable site
Structure and immunogenicity of novel trimeric HIV-1 Env immunogens
Structure and immunogenicity of novel trimeric HIV-1 Env immunogens
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究